Erenumab

(Aimovig)

Erenumab

Drug updated on 11/15/2023

Dosage FormInjection (subcutaneous; 70 mg/mL, 140 mg/mL)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the preventive treatment of migraine in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Aimovig (erenumab) Prescribing Information.2023Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.2023Cephalalgia: International Headache Society
Erenumab efficacy in migraine headache prophylaxis: A systematic review.2023International immunopharmacology
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.2023Cephalalgia: International Headache Society
Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review. 2023Cureus
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies. 2023Clinical Drug Investigation
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. 2023Journal of Headache and Pain
Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis. 2023The Clinical Journal of Pain
Gender bias in clinical trials of biological agents for migraine: A systematic review. 2023PLoS One
Erenumab efficacy in migraine headache prophylaxis: A systematic review. 2023International Immunopharmacology
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. 2022The Journal of Headache and Pain
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.2022The Journal of Headache and Pain
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.2022European Journal of Medical Research
Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.2022Headache: The Journal of Head and Face Pain
Long-term safety and effectiveness of erenumab in patients with migraine: a systematic review and single-arm meta-analysis.2022Clinical Drug Investigation
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. 2021Expert Opinion on Drug Safety
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. 2021Expert Opinion on Drug Safety
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. 2021Cephalalgia
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene‑related peptide and its receptor for the prevention of chronic migraine: a network meta‑analysis of randomized controlled trials.2021Neurotherapeutics
Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta analysis.2021CNS Drugs
Clinical review report: erenumab (Aimovig).2020CADTH
Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety.2019Drugs
Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials.2019Medicine
CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data.2019Cephalalgia
Assessment report: Aimovig. 2018EMA
Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value. 2018ICER

Clinical Practice Guidelines